It's awfully quiet here. The question I might ask is does anyone see the stock rallying by the end of the year, or will tax loss selling have us looking at even lower lows this year.
As I see it, we could have substantial positive news in the next few quarters, but barring something occurring ahead of time, I don't know of anything really positive I expect by the end of this year.
While I believe we're greatly under priced, I don't know that the Street will see that before something substantial in the way of news comes out. I'm speaking of really positive Phase II or III news, not preclinical data. An NDA filing or new Phase III Trial beginning would be positive, as would a partnership for any of the drugs we routinely discuss.
While I believe we've now put the bad news behind us, though dilution is never completely behind you, I believe it will largely be up from here, but probably not until the tax loss season ends.
Gary
Market Data 
Markets 
AI
